Stockscreener 앱 받기
79.90
0.11%
-0.09
전일 마감가:
$79.99
열려 있는:
$79.59
하루 거래량:
2.82M
Relative Volume:
0.64
시가총액:
$247.80B
수익:
$56.53B
순이익/손실:
$8.32B
주가수익비율:
29.82
EPS:
2.6798
순현금흐름:
$8.49B
1주 성능:
-1.32%
1개월 성능:
+8.00%
6개월 성능:
+5.62%
1년 성능:
-8.48%
1일 변동 폭
$79.37
$80.09
1주일 범위
$79.35
$81.52
52주 변동 폭
$61.24
$87.67
아스트라제네카 ADR Stock (AZN) Company Profile
명칭
Astrazeneca PLC
전화
44 20 3749 5000
주소
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
AZN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
79.90 | 248.01B | 56.53B | 8.32B | 8.49B | 2.6798 |
아스트라제네카 ADR Stock (AZN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-15 | 개시 | Exane BNP Paribas | Outperform |
| 2025-02-13 | 업그레이드 | UBS | Neutral → Buy |
| 2025-02-12 | 개시 | Morgan Stanley | Overweight |
| 2024-11-20 | 업그레이드 | UBS | Sell → Neutral |
| 2024-11-06 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-09-13 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-16 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-02-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Sell |
| 2024-01-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-09-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-07-12 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-05 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-04-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2022-09-15 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | 업그레이드 | Argus | Hold → Buy |
| 2022-06-14 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-11 | 업그레이드 | DZ Bank | Sell → Hold |
| 2021-12-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-12 | 재개 | JP Morgan | Overweight |
| 2021-04-12 | 다운그레이드 | Argus | Buy → Hold |
| 2021-03-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-25 | 업그레이드 | UBS | Neutral → Buy |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-12-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | 업그레이드 | UBS | Sell → Neutral |
| 2020-11-11 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2019-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-10-25 | 업그레이드 | Liberum | Hold → Buy |
| 2019-04-02 | 다운그레이드 | UBS | Neutral → Sell |
| 2019-02-05 | 개시 | Exane BNP Paribas | Outperform |
| 2019-01-25 | 업그레이드 | Shore Capital | Hold → Buy |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-08-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-03-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-02-06 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-05 | 재확인 | Bernstein | Outperform |
| 2018-01-18 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-12-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-10-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
모두보기
아스트라제네카 ADR 주식(AZN)의 최신 뉴스
AstraZeneca Announces Current Share Capital and Voting Rights - TipRanks
Published on: 2025-09-01 16:47:49 - خودرو بانک
AstraZeneca’s baxdrostat shows promise in Phase III hypertension trial - Clinical Trials Arena
What candlestick patterns are forming on AstraZeneca PLC Depositary ReceiptPortfolio Return Report & High Yield Equity Trading Tips - Newser
After this weekend’s news, is it time to look again at the AstraZeneca share price? - MSN
Signal strength of AstraZeneca PLC Depositary Receipt stock in tech scannersEarnings Recap Report & Long-Term Safe Investment Ideas - Newser
Multi asset correlation models including AstraZeneca PLC Depositary ReceiptPortfolio Performance Report & Reliable Entry Point Trade Alerts - Newser
How to recover losses in AstraZeneca PLC Depositary Receipt stockJuly 2025 Reactions & Community Supported Trade Ideas - Newser
What momentum shifts mean for AstraZeneca PLC Depositary ReceiptJuly 2025 Breakouts & AI Powered Market Trend Analysis - Newser
Real time scanner hits for AstraZeneca PLC Depositary Receipt explainedForecast Cut & High Win Rate Trade Alerts - Newser
What institutional flow reveals about AstraZeneca PLC Depositary ReceiptEarnings Performance Report & AI Driven Stock Movement Reports - Newser
AstraZeneca's Hypertension Drug Lowers Blood Pressure in 'Meaningful, Sustained' Manner - MarketScreener
Technical analysis overview for AstraZeneca PLC Depositary Receipt stock2025 Volume Leaders & Technical Confirmation Trade Alerts - Newser
Shareholders that lost money on AstraZeneca PLC (AZN) should contact Levi & Korsinsky about pending Class ActionAZN - ACCESS Newswire
AstraZeneca to seek approval for antihypertensive this year (AZN) - Seeking Alpha
AstraZeneca Faces Close Race With Mineralys After Phase III Hypertension Readout - insights.citeline.com
15.7mmHg Blood Pressure Reduction: AstraZeneca's Novel Drug Shows Breakthrough in Treatment-Resistant HTN - Stock Titan
AstraZeneca to seek approval for blood pressure drug by year-end - MarketScreener
AstraZeneca PLC Depositary Receipt Included in Top Momentum ScanJuly 2025 Update & Technical Pattern Based Signals - beatles.ru
What does recent volatility data suggest for AstraZeneca PLC Depositary Receipt2025 Trade Ideas & Technical Buy Zone Confirmations - Newser
Using Ichimoku Cloud for AstraZeneca PLC Depositary Receipt technicalsWeekly Trade Summary & Free AI Powered Buy and Sell Recommendations - Newser
Is it time to cut losses on AstraZeneca PLC Depositary ReceiptWeekly Trade Report & Safe Capital Growth Plans - Newser
SGLT2 Inhibitors Market to Hit USD 29.73 Billion by 2032, Driven by Expanding Diabetes Management and Cardiovascular Benefits – SNS Insider - GlobeNewswire Inc.
AstraZeneca PLC (AZN) Oncology Sales Hit $12B in H1 2025 - MSN
AstraZeneca Challenges Colo. Law Over Drug Pricing Rules - Law360
Characterization of Astrazeneca’s AZD-0233 for cardiovascular disease - BioWorld MedTech
Gout Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review | AstraZeneca, R-Pharm, Allena Pharma, JW Pharma, Hinova pharma, Jiangsu Hengrui Medicine, Selecta Biosciences, LG Chem - Barchart.com
Is a relief rally coming for AstraZeneca PLC Depositary Receipt holdersRate Cut & Real-Time Volume Analysis - Newser
Evaluating AstraZeneca PLC Depositary Receipt with trendline analysisJuly 2025 Pullbacks & Short-Term Swing Trade Alerts - Newser
아스트라제네카 ADR (AZN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):